Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines Ltd has submitted a routine compliance certificate to BSE from its Registrar and Transfer Agent, Purva Sharegistry (India) Pvt Ltd, for the quarter ended 30 September 2025. The certificate confirms that share certificates received from depository participants for dematerialisation during the quarter were duly processed — accepted or rejected — and that the cancelled physical certificates were mutilated after verification, with the depositories' names substituted as registered owners within SEBI-prescribed timelines. The filing includes a list of around 21 individual shareholders (totalling roughly 1,650 shares) who converted their physical share certificates into demat form between 1 July and 24 September 2025. The letter is signed by Director Praveenchand Bafna.
This is a routine, procedural regulatory filing with no impact on the company's financials, operations, or share price. It simply evidences timely processing of dematerialisation requests.